Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MUC1 Dendritic Cell Vaccine · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
| Arm | Type | Description |
|---|---|---|
| Cvac Treatment Group | EXPERIMENTAL | Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment. |
| Name | Type | Description |
|---|---|---|
| MUC1 Dendritic Cell Vaccine (Cvac) | BIOLOGICAL | The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac). Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks). |
Inclusion Criteria: * Female patients ≥ 18 years old with histologically confirmed Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in CAN-003 * Able and willing to undergo mononuclear cell (MNC) collection (if required for patients who do not have ...
MUC1 Dendritic Cell Vaccine is an investigational cancer vaccine being studied for the treatment of epithelial ovarian cancer. It is designed to target the MUC1 antigen, which is expressed on tumor cells. The vaccine is currently in Phase 2 clinical development and has been evaluated in a completed clinical trial.
MUC1 Dendritic Cell Vaccine is being developed by Immutep Limited, a biopharmaceutical company. The company's stock is traded under the ticker symbol IMMP. The vaccine is currently in Phase 2 clinical development for the treatment of epithelial ovarian cancer.
MUC1 Dendritic Cell Vaccine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The vaccine is being studied for the treatment of epithelial ovarian cancer, and one Phase 2 clinical trial has been completed.
MUC1 Dendritic Cell Vaccine has been evaluated in one clinical trial with the identifier NCT01617629. This Phase 2 study, titled 'Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study,' was completed and enrolled 9 female patients with epithelial ovarian cancer in the United States and Australia.
MUC1 Dendritic Cell Vaccine is classified as a monoclonal antibody modality, though it functions as a cancer vaccine. It is designed to target the MUC1 antigen, which is present on ovarian cancer cells. The vaccine is currently in Phase 2 clinical development for epithelial ovarian cancer.